메뉴 건너뛰기




Volumn 10, Issue 9, 2015, Pages e95-e96

Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; PROTEIN RET; STEROID; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; KIF5B-RET FUSION PROTEIN, HUMAN; ONCOPROTEIN; PYRROLE DERIVATIVE;

EID: 84940107951     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000611     Document Type: Letter
Times cited : (16)

References (4)
  • 1
    • 84925876884 scopus 로고    scopus 로고
    • Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer
    • [Epub ahead of print]
    • Falchook GS, Ordonez NG, Bastida CC, Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. J Clin Oncol 2014. [Epub ahead of print].
    • (2014) J Clin Oncol
    • Falchook, G.S.1    Ordonez, N.G.2    Bastida, C.C.3
  • 2
    • 84926408835 scopus 로고    scopus 로고
    • Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
    • Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY, Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer 2015 88 208 214
    • (2015) Lung Cancer , vol.88 , pp. 208-214
    • Tsai, T.H.1    Wu, S.G.2    Hsieh, M.S.3    Yu, C.J.4    Yang, J.C.5    Shih, J.Y.6
  • 3
    • 33749544080 scopus 로고    scopus 로고
    • An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
    • Kim DW, Jo YS, Jung HS, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006 91 4070 4076
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 4070-4076
    • Kim, D.W.1    Jo, Y.S.2    Jung, H.S.3
  • 4
    • 84878858856 scopus 로고    scopus 로고
    • Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas
    • Drilon A, Wang L, Hasanovic A, Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013 3 630 635
    • (2013) Cancer Discov , vol.3 , pp. 630-635
    • Drilon, A.1    Wang, L.2    Hasanovic, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.